Joint Programming Initiative on Antimicrobial Resistance
 

What is antimicrobial resistance?

Antimicrobial resistance (AMR) is resistance of a microorganism to an antimicrobial medicine to which it was originally sensitive. Resistant organisms (they include bacteria, fungi, viruses and some parasites) are able to withstand attack by antimicrobial medicines, such as antibiotics, antifungals, antivirals, and antimalarials, so that standard treatments become ineffective and infections persist increasing risk of spread to others. The evolution of resistant strains is a natural phenomenon that happens when microorganisms are exposed to antimicrobial drugs, and resistant traits can be exchanged between certain types of bacteria. The misuse of antimicrobial medicines accelerates this natural phenomenon. Poor infection control practices encourages the spread of AMR.

Why is antimicrobial resistance a global concern?

  1. AMR kills
  2. AMR hampers the control of infectious diseases
  3. AMR threatens a return to the pre-antibiotic era
  4. AMR increases the costs of health care
  5. AMR jeopardizes health-care gains to society
  6. AMR threatens health security, and damages trade and economies

*Reference: WHO WEBSITE http://www.who.int/mediacentre/factsheets/fs194/en

Want to know more about Antimicrobial Resistance? Check out our video.

Coordination benefits

The global and multifaceted problem of antimicrobial resistance will demand vast and versatile solutions. Comprehensive interventions to address the problem are needed, involving a wide range of sectors of society; policy makers, health care, education, industry, environmental agencies, agriculture, veterinary medicine, research, and other areas.

The JPIAMR cannot address all aspects of the problem, but may show a way forward by producing new research and creating networks that can create long-term momentum for other areas in society. There is an urgent need for interdisciplinary and public-private partnerships to support research in the antimicrobial resistance area. Exchanges between industry, public health bodies, and academic bodies will entail not only sharing costs, but also coordination of the respective research activities. This is where JPIAMR can make a difference.

Factsheet on AMR:
http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/basic_facts/Pages/factsheet_general_public.aspx

World economic forum report:
http://reports.weforum.org/global-risks-2013/risk-case-1/the-dangers-of-hubris-on-human-health/

http://en.wikipedia.org/wiki/Antimicrobial_resistance

Share this page
Tweet about this on TwitterShare on FacebookShare on Google+